Explore /
Poster
/ A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR-Cas9–engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (CARBON).

A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR-Cas9–engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (CARBON).

Authors

Joseph McGuirk

Department of Blood and Bone Marrow Transplant, The University of Kansas Medical Center, Kansas City, KS

Joseph McGuirk , Carlos R. Bachier , Michael Russell Bishop , P. Joy Ho , Hemant S. Murthy , Michael J. Dickinson , Joseph E. Maakaron , Charalambos Andreadis , Armin Ghobadi , Edmund K. Waller , Mark Daniel Benton , Susanna Suh , Huansheng Xu , Ewelina Morawa , Farrukh Tauseef Awan , Paul Shaughnessy , Constantine Si Lun Tam , Nicolaus Kroeger , Richard T. Maziarz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04035434

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS7570)

DOI

10.1200/JCO.2021.39.15_suppl.TPS7570

Abstract #

TPS7570

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Annual Meeting

$Safety and early efficacy results of phase 1 study of affinity tuned and trackable AIC100 CAR T cells in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers.$